Precigen, Inc. (NASDAQ:PGEN) reported mixed results for the fourth quarter on Wednesday.

The company posted a quarterly loss of 1 cent per share which beat the analyst consensus estimate of losses of 8 cents per share. The company reported quarterly sales of $4.565 million which missed the analyst consensus estimate of $8.286 million.

“With the FDA approval and launch of PAPZIMEOS, 2025 marked a transformational year for Precigen as we transitioned from a clinical-stage to a commercial-stage company and recognized our first commercial product revenues toward the end of the year,” said Helen Sabzevari, PhD, President and CEO of Precigen. “We are seeing strong alignment within the physician community around PAPZIMEOS as the first-line standard of care for adults with RRP, supported by its profile as the only approved therapy for RRP, the compelling safety and efficacy data, and the encouraging durability of response observed to date. This is an exciting time for Precigen, and we look forward to sharing further updates during our call regarding the significant momentum we’re seeing in the first quarter.”

Precigen shares fell 3.5% to trade at $3.84 on Thursday.

These analysts made changes to their price targets on Precigen following earnings announcement.

  • HC Wainwright & Co. analyst Swayampakula Ramakanth maintained Precigen with a Buy and raised the price target from $9 to $10.
  • Citizens analyst Jason N. Butler maintained the stock with a Market Outperform and raised the price target from $8 to $9.

Considering buying PGEN stock? Here’s what analysts think:

Photo via Shutterstock